Aurobindo Pharma Ltd stock (INE406A01037): up 0.43% on NSE
Aurobindo Pharma Ltd shares rose 0.43% to 1,485.10 INR on May 8, 2026, amid Indian pharma firms’ $19.1B US expansion pledges.
Aurobindo Pharma Ltd stock advanced 0.43% to 1,485.10 INR on May 8, 2026, at 15:30 IST on the National Stock Exchange of India, according to NSE India as of 08-May-2026. This movement comes as Indian pharmaceutical majors, including Aurobindo, committed $19.1 billion to US expansion, highlighting growing exposure to the American market for US investors.
As of: 12.05.2026
By the editorial team – specialized in equity coverage.
At a glance
- Name: Aurobindo Pharma Ltd
- Sector/industry: Pharmaceuticals
- Headquarters/country: India
- Core markets: US, Europe, emerging markets
- Key revenue drivers: Generics, APIs, injectables
- Home exchange/listing venue: NSE/BSE (AUROPHARMA)
- Trading currency: INR
Official source
For first-hand information on Aurobindo Pharma Ltd, visit the company’s official website.
Aurobindo Pharma Ltd: core business model
Aurobindo Pharma Ltd develops, manufactures and markets active pharmaceutical ingredients (APIs), generics and finished dosage formulations. The company operates 25 facilities across India and has a strong focus on high-value generics for the US market, which accounts for over 50% of its revenue. Aurobindo supplies a wide range of molecules including antibiotics, anti-retrovirals and cardiovascular drugs, positioning it as a key player in global generics supply chains relevant to US healthcare providers.
Main revenue and product drivers for Aurobindo Pharma Ltd
The US remains Aurobindo’s largest market, driving majority of sales through generic drugs for chronic therapies. Europe and other regions contribute the balance, with recent emphasis on complex injectables and biosimilars. Key products include generics for penicillin derivatives and oncology treatments, benefiting from steady US demand amid rising drug costs.
Why Aurobindo Pharma Ltd matters for US investors
Aurobindo Pharma Ltd holds relevance for US investors through its dominant role as a generics supplier to American pharmacies and hospitals. The company’s $19.1 billion industry-wide US investment pledge signals expanded manufacturing footprint stateside, potentially enhancing supply chain resilience for US patients. Listed on Indian exchanges but with heavy US revenue exposure, it offers diversified access to pharma growth via ADRs or direct trading.
Conclusion
Aurobindo Pharma Ltd demonstrated positive price momentum with a 0.43% gain on May 8, 2026, alongside broader Indian pharma commitments to US expansion. The company’s generics focus and US market reliance provide steady revenue streams, though exposed to regulatory and pricing pressures. Investors track ongoing developments in its American growth strategy.
Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.
